Latest Incentive Structures News

Wesfarmers Limited has announced a fully franked special dividend of AUD 0.40 per share alongside a substantial AUD 1.10 capital return, both payable on 4 December 2025, marking a significant milestone in its 2025 capital management strategy.

Steadfast Group reveals the remuneration package for new Acting CEO Tim Mathieson, highlighting a $1 million fixed salary plus substantial performance incentives for FY26.

Kingfisher Mining has appointed geologist Chris Bittar as Managing Director, aiming to leverage his expertise to advance its NSW and Western Australian mineral projects.

Vault Minerals Limited has announced a significant security consolidation, reducing its ordinary shares and performance rights by a factor of more than six. The move, effective from mid-November, aims to streamline the company’s capital structure ahead of resumed trading.

Orora Limited has finalized its strategic portfolio transformation, delivering solid FY25 financial results despite softness in its glass segment. The company outlines a cautiously optimistic FY26 outlook, underpinned by sustainability progress and investments in beverage packaging innovation.

Benz Mining Corp. reports a landmark 79-metre intercept grading 4.4 grams per tonne gold at its Zone 126 prospect, marking the thickest high-grade hit to date at the Glenburgh Gold Project. The company is accelerating drilling and aligning management incentives with ambitious resource growth targets.

Jatcorp has officially appointed Dr Xinpeng (Sean) Li as its CEO, locking in a three-year contract that underscores a strategic focus on sustainable growth and innovation.

PolyNovo Limited stands to benefit from proposed U.S. Medicare changes that introduce a flat reimbursement rate for outpatient wound care skin substitutes, potentially reshaping the competitive landscape in favour of cost-effective, clinically proven products.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Zoono Group Limited has raised an additional A$992,000 through a shortfall placement, boosting its working capital to support global expansion of its shelf-life extension technology. The company also linked CEO share incentives to ambitious sales targets, signaling confidence in growth prospects.

City Chic Collective Limited reported a significant reduction in its FY25 net loss alongside modest revenue growth, setting the stage for a potential turnaround in FY26 backed by cost savings and a clean debt facility.